Healthcare >> CEO Interviews >> October 12, 2001
ANNEMARIE B. MOSELEY, has been President and Chief Executive Officer of
Osiris Therapeutics since the fourth quarter of 1999. Prior to her
current position at the company, Dr. Moseley served Osiris as Sr. Vice
President of Clinical and Regulatory Affairs. Before joining Osiris, Dr.
Moseley served as Director of Clinical Gene Therapy at SyStemix, a
Novartis company, where she was responsible for clinical development of
HIV stem cell gene therapy. Before that, she held the position of Sr.
Vice President of Clinical/Regulatory Affairs for Titan Pharmaceuticals,
Inc., and Applied Immune Sciences, a subsidiary of Rhone Poulenc Rohrer.
Her responsibilities included the clinical and regulatory management of
programs in cellular and gene therapy products for cancer and infectious
diseases. Dr. Moseley received a Ph.D. in Physiology and Biochemistry
from Utah State University and an MD from Baylor College of Medicine,
where she completed a residency in Internal Medicine, a clinical
investigator program in Immunology, and a clinical stem cell gene
therapy fellowship in Medical and Molecular Genetics. Profile
Dr. Moseley: Osiris is a privately held biotechnology company that was
founded in early 1993. Our primary technology is based on
